Skip to main content
Log in

Pharmacokinetics and bioavailability of digitoxin by a specific assay

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5% using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Armitage P (1971) Statistical methods in medical research. Blackwell Scientific Publications, Boston 354–355

  • Beermann B, Hellström K, Rosén A (1971) Fate of orally administered3H-digitoxin in man with special reference to the absorption. Circulation 43: 852–861

    CAS  PubMed  Google Scholar 

  • Böttcher H, Lüllmann H, Proppe D (1973) Comparison of digoxin with some digitoxin metabolites on cat heart lung preparation. Eur J Pharmacol 22: 109–111

    PubMed  Google Scholar 

  • Dutta S, Marks BH, Stephen PM (1976) The uptake and subcellular distribution of radio-labelled metabolites of digitoxin in the guinea-pig isolated perfused heart. Br J Pharmacol 56: 437–441

    CAS  PubMed  Google Scholar 

  • Flasch H, Heinz N (1978) Correlation between inhibition of (Na+, K+) membrane — ATPase and positive inotropic activity of cardenolides in isolated papillary muscles of guinea pig. Naunyn Schmiedebergs Arch Pharmacol 304: 37–44

    Article  CAS  PubMed  Google Scholar 

  • Graves PE, Perrier D, Marcus FI (1983) Quantitation of digitoxin and the bis- and monodigitoxosides of digitoxigenin in serum. J Chromatogr 278: 397–405

    CAS  PubMed  Google Scholar 

  • Jelliffe RW, Bechtol LD, Crabtree R (1980) The bioavailability of digitoxin. Clin Pharmacol Ther 27: 261

    Google Scholar 

  • Lukas DS (1971) Some aspects of the distribution and disposition of digitoxin in man. Ann NY Acad Sci 179: 338–361

    CAS  PubMed  Google Scholar 

  • Perrier D, Mayersohn M, Marcus FI (1977) Clinical pharmacokinetics of digitoxin. Clin Pharmacokinetics 2: 292–311

    CAS  Google Scholar 

  • Peters V, Funcke C, Hausamen TV, Staib W (1978) Quantitative studies on the acid hydrolysis of digitoxin. Arzneimittelforsch 28: 750–751

    CAS  PubMed  Google Scholar 

  • Rasmussen K, Jervell J, Storstein O (1971) Clinical use of a bioassay of serum digitoxin activity. Eur J Clin Pharmacol 3: 236–242

    Article  CAS  PubMed  Google Scholar 

  • Storstein L (1976) Studies on digitalis VII: influence of nephrotic syndrome on protein binding, pharmacokinetics and renal excretion of digitoxin and cardioactive metabolites. Clin Pharmacol Ther 20: 158–166

    CAS  PubMed  Google Scholar 

  • Storstein L (1977) Studies on digitalis VIII: digitoxin metabolism on a maintenance regimen and after a single dose. Clin Pharmacol Ther 21: 125–140

    CAS  PubMed  Google Scholar 

  • Vöhringer HF, Rietbrock N (1974) Metabolism and excretion of digitoxin in man. Clin Pharmacol Ther 16: 796–806

    PubMed  Google Scholar 

  • Wirth KE, Frölich JC, Hollifield JW, Falkner FC, Sweetman BS, Oates JA (1976) Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 9: 345–354

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by a Clinician-Scientist Award from the American Heart Association

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacFarland, R.T., Marcus, F.I., Fenster, P.E. et al. Pharmacokinetics and bioavailability of digitoxin by a specific assay. Eur J Clin Pharmacol 27, 85–89 (1984). https://doi.org/10.1007/BF02395212

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02395212

Key words

Navigation